New drug aims to fight cancer while protecting the heart
NCT ID NCT06815575
Summary
This is a first-in-human study to test the safety of a new drug called RC220 when given with the common chemotherapy drug doxorubicin. It will involve about 53 adults with advanced solid tumors who may benefit from anthracycline treatment. The main goals are to find the safest dose and see if RC220 can help protect the heart from doxorubicin's known side effects while fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Care Foundation
RECRUITINGMiranda, New South Wales, 2228, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gosford Hospital
RECRUITINGGosford, New South Wales, 2250, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prince of Wales Hospital
RECRUITINGShatin, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Queen Mary Hospital
RECRUITINGHong Kong, 999077, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wyong Hospital
RECRUITINGWyong, New South Wales, 2259, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.